BioMarin Pharmaceutical Inc.
BMRN
Xếp hạng trong cổ phiếu
#1984
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market... BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
Giá cổ phiếu
$54.14
Vốn hóa thị trường
$10.48B
Thay đổi (1 ngày)
-0.99%
Thay đổi (1 năm)
1.60%
Quốc gia
US
Giao dịch BioMarin Pharmaceutical Inc. (BMRN)
Danh mục
Healthcare
EPS của BioMarin Pharmaceutical Inc. (BMRN)
EPS tính đến June 2026 TTM: $0.38
Theo các báo cáo tài chính mới nhất và giá cổ phiếu của BioMarin Pharmaceutical Inc., EPS hiện tại của công ty (TTM) là $0.38. Vào cuối năm 2024, công ty có EPS là $2.25, tăng so với EPS năm 2023 là $0.89.
Lịch sử EPS của BioMarin Pharmaceutical Inc. từ 2000 đến 2026
EPS vào cuối mỗi năm
| Năm | EPS | Thay đổi |
|---|---|---|
| 2026 (TTM) | $0.38 | 171.43% |
| 2025 | $0.14 | -93.78% |
| 2024 | $2.25 | 152.81% |
| 2023 | $0.89 | 17.11% |
| 2022 | $0.76 | -317.14% |
| 2021 | $-0.35 | -107.37% |
| 2020 | $4.75 | -3,753.85% |
| 2019 | $-0.13 | -70.45% |
| 2018 | $-0.44 | -34.33% |
| 2017 | $-0.67 | -82.37% |
| 2016 | $-3.80 | 255.14% |
| 2015 | $-1.07 | 16.30% |
| 2014 | $-0.92 | -28.13% |
| 2013 | $-1.28 | 34.74% |
| 2012 | $-0.95 | 97.92% |
| 2011 | $-0.48 | -124.12% |
| 2010 | $1.99 | -40,712.24% |
| 2009 | 0.00 | -101.58% |
| 2008 | $0.31 | -293.75% |
| 2007 | $-0.16 | -52.94% |
| 2006 | $-0.34 | -68.52% |
| 2005 | $-1.08 | -62.89% |
| 2004 | $-2.91 | 138.52% |
| 2003 | $-1.22 | -15.86% |
| 2002 | $-1.45 | -12.12% |
| 2001 | $-1.65 | 58.65% |
| 2000 | $-1.04 | 0.00% |
EPS cho các công ty hoặc đối thủ cạnh tranh tương tự
| Công ty | EPS | Chênh lệch EPS | Quốc gia |
|---|---|---|---|
| $17.32 | 4,457.89% |
US
|
|
| $-7.98 | -2,200.00% |
US
|
|
| $-5.29 | -1,492.11% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 7,200.00% |
NL
|
